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Abstract 
Introduction: In the context of IPF, respiratory related admissions to hospital are associated 
with a high morbidity and short-term mortality with significant burden on secondary care 
services.  It has yet to be determined how to accurately identify patients at risk of acute 
respiratory deterioration (ARD) or the prognosticating factors. 
Objective: We sought to define the characteristics of hospitalised ARD-IPF patients in a real-
world cohort and investigate factors associated with worse outcomes. Specifically, we wished 
to determine the association between baseline CURB-65 and NEWS2 and mortality in IPF, 
given illness severity scores have not previously been validated in this cohort.  
Methods: Single-centre retrospective observational cohort study. 
Results: Of 172 first hospitalisations for ARD, 27 admissions (15.7%) were due to an acute 
exacerbation of IPF (AE-IPF), 28 (16.3%) secondary to cardiac failure/fluid overload and 17 
due to pneumonia (9.9%). Other admissions related to lower respiratory tract infection, extra-
parenchymal causes and those without a specific trigger. Baseline patient characteristics were 
comparable for all underlying aetiologies of ARD-IPF. Treatment pathways did not differ 
significantly between AE-IPF and other causes of ARD-IPF.  Short term mortality was high, with 
approximately 22% patients dying within 30 days. Illness severity scores (NEWS-2 and CURB-
65) were independent predictors of mortality in multivariable logistic regression modelling. 
Conclusions: Our findings suggest significant mortality related to hospitalisation with ARD-IPF 
of any underlying cause. Our data supports the use of CURB-65 and NEWS-2 scores as illness 
severity scores that can provide a simple tool to help future prognostication in IPF. Research 
should be aimed at refining the management of these episodes, to try to reduce mortality, 
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Introduction
Idiopathic pulmonary fibrosis (IPF) remains a rare but significant respiratory condition, 
defined by progressive lung fibrosis of unknown aetiology (1). Whilst some patients 
experience a steady decline in the their lung function over time, others experience sudden 
acute deteriorations that follow a period of relative stability (2). This heterogeneous disease 
course amongst individuals with IPF makes it challenging for healthcare professionals to 
predict the outcome of an individual patient, although the average life expectancy is only 3-5 
years from diagnosis (3). 
Collard et al. (4) recently published a conceptual framework for acute respiratory 
deteriorations (ARD) in IPF, subcategorising the aetiology of episodes as extra-parenchymal 
or parenchymal in origin. The presence of new diffuse pulmonary infiltrates on the 
background of established fibrosis, not fully explained by fluid overload or cardiac failure, 
describes an acute exacerbation of IPF (AE-IPF); a parenchymal cause of ARD-IPF whose 
definition has recently been revised to include episodes that may be ‘triggered’ by insults such 
as infection or those considered to be idiopathic in nature (4). It has been suggested that the 
prognosis of AE-IPF differs from other parenchymal causes of ARD-IPF (5); potentially 
highlighting the value of careful clinical phenotyping.
In the context of IPF, respiratory related admissions to hospital are associated with a high 
morbidity and short-term mortality with significant burden on secondary care services (6-8), 
although the factors that predict adverse outcomes in individuals are not fully understood. 
Early stratification of patients might be useful in planning referral for transplantation where 
applicable and/or advanced care planning discussions.
The CURB-65 score is an illness severity score, originally validated in pneumonia, enabling 
stratification of in-hospital mortality based on a 6-point score; one point for each of confusion, 
urea >7 mmol/l, respiratory rate (RR) ≥30/min, low systolic (<90 mm Hg) or diastolic (≤60 mm 
Hg) blood pressure (BP), age ≥65 years (9). It has subsequently been shown to predict in-
hospital mortality in exacerbations of Chronic Obstructive Pulmonary Disease (COPD) (10, 11). 
The National Early Warning Score (NEWS) is an alternative bedside tool incorporating seven 
objective measures of clinical status; RR, oxygen saturation, use of supplemental oxygen, 
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rapidly identify in-hospital patients at risk of deterioration, and has subsequently been shown 
to predict in hospital mortality in older patients (12-15).  To date, no study has assessed the 
prognostic value of these illness severity scores in predicting short term outcomes in ARD-IPF.
The aim of this study was to describe the characteristics of hospitalised ARD-IPF patients in a 
real-world cohort and investigate factors associated with worse outcomes. Specifically we 
sought to determine the association between CURB-65 and NEWS-2 baseline illness severity 
scores and mortality. 
Methods
Study design
This was a retrospective, single-centre observational cohort study undertaken at a large 
secondary care institution in the UK with specialist Interstitial Lung Disease (ILD) services 
available on site. The institution provides secondary and tertiary care to patients with 
interstitial lung disease with the South West of England supporting a local population of 
approximately 2 million. The study was approved by the Health Research Authority and health 
and Care Research Wales (HCRW), United Kingdom (IRAS 260771). 
Study Subjects
Consecutive patients admitted to the study centre with an ARD-IPF between January 2014 
and December 2018 were included. Participants were identified retrospectively from hospital 
records using the International Classification of Diseases Tenth Revision (ICD-10) diagnostic 
code J84.1. As J-84.1 includes other fibrotic pulmonary diseases, validation of the clinical 
coding was performed on all patients in the cohort, cross-referencing the ICD code with 
written documentation of an ARD-IPF (i.e. patient was admitted with deteriorating 
respiratory function, under 1 month in duration, with a previous or concurrent diagnosis of 
IPF). All original diagnoses of IPF had been made by multidisciplinary team (MDT) consensus 
in accordance with 2011 ATS/ERS/JRS/ALAT guidelines (1). Throughout the process of data 
collection, the diagnosis of IPF was verified according to 2018 diagnostic criteria (3).
Outcome measures
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1. Extra-parenchymal causes were defined as pleural effusion, pneumothorax or 
pulmonary embolism.
2. AE-IPF was diagnosed according to the Collard (4) revised criteria: 
previous/concurrent IPF, worsening breathlessness <1 month duration, new bilateral 
ground-glass opacity and/or consolidation indicating widespread acute lung 
injury/diffuse alveolar damage, superimposed on a background pattern consistent 
with usual interstitial pneumonia (UIP) pattern on CT imaging, and deterioration not 
fully explained by cardiac failure or fluid overload. The definition of AE-IPF was 
broadened to include patients who had not had a CT Chest performed, but 
demonstrated new multilobar bilateral opacification on chest X-RAY, as interpreted by 
a Consultant Radiologist. AE-IPF was further sub-categorised into
a)  triggered , defined as having a clear precipitant, for example infection, 
drugs or aspiration or 
b) idiopathic. 
3. Not-AE-IPF - This included a group of patients with other parenchymal causes for their 
ARD-IPF, not attributed to an acute exacerbation:
a) Lower respiratory tract infection (LRTI), as a cause for ARD was defined in 
those patients with a normal CT and CXR but presence of C-reactive protein 
CRP >6mg/L .
b) Cardiac failure/fluid overload
c) Pneumonia
d) Disease progression
e) No specific trigger – admission possibly related to anxiety or for 
symptomatic control and palliation
4. Unclassified ARD-IPF was used to refer to patients without CT Chest performed on 
admission and with a CXR that did not show any new changes compared to previous 
imaging, as interpreted by a consultant radiologist. 
The primary outcome was mortality with a secondary outcome of overall length of stay. 
Independent variables were baseline illness severity scores, in the form of CURB-65 (9) and 
National Early Warning Score-2 (NEWS-2) (16). Data were collated on potential confounding 
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vaccination status and use of antifibrotic medications (for 6 months or more prior to 
admission).  Gender-Age-Physiology (GAP) scores were calculated (17). The investigative and 
treatment pathway were recorded for each inpatient stay. 
Statistical analysis
Patient characteristics were tabulated based on the underlying aetiology of ARD-IPF as 
defined above. Categorical variables were presented as counts with percentages. All 
continuous data were non-parametric and therefore presented with medians and 
interquartile range (IQR). Differences between patient groups were evaluated using Mann 
Whitney U and Kruskal Wallis tests for continuous data and Fisher’s exact test or Chi-squared 
testing for categorical data. 
For the primary analysis, univariable and multivariable logistic regression analyses were 
performed to explore the relationship between baseline severity scores and mortality. The 
factors used in the multivariable model were decided a priori and included male gender, age, 
smoking status, GAP score, white cell count, neutrophil to lymphocyte ratio (NLR), C-reactive 
protein (CRP), CURB-65 and NEWS-2 score. Receiver operating characteristic curves were 
used to propose discriminating thresholds for variables of interest. For all tests a P < 0.05 was 
considered statistically significant. Data were analysed using Prism Version 8.0 (Graphpad 
software, San Diego, USA), with STATA (StataCorp, Texas, USA) for logistic regression analysis. 
Results
Patient demographics
A total of 232 episodes of ARD-IPF were identified in 172 patients from January 2014 to 
December 2018. The majority of patients presenting with their first ARD-IPF were male (63% 
(n=108 of 172) and ex-smokers (56% (n=97)), with a median age of 77 years (IQR 70-85) (see 
Table 1 and Supplementary Table 1). Patients had moderate restrictive disease with a median 
GAP score of 5, corresponding to GAP stage II.
Most patients had a known consensus diagnosis of IPF prior to admission (76.7%, n=132), with 
radiological pattern of definite usual interstitial pneumonia (UIP) in approximately half of all 
patients. Surgical lung biopsy had been rarely required to achieve the MDT consensus IPF 
diagnosis (n=15, 8.7%). In over 40% of first ARD-IPF presentations, the admission NEWS-2 
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Underlying aetiology of ARD
Figure 1. depicts the underlying aetiology of first admissions with ARD-IPF (Supplemental 
Table 1. provides details of the underlying aetiology of all ARD-IPF admissions). Of the 172 
first hospitalisations for ARD, nearly half (n=80, 46.5%) were due to parenchymal causes other 
than AE-IPF, specifically cardiac failure (n=28, 16.3%), pneumonia (n=17, 9.9%), disease 
progression (n=13, 7.6%) and lower respiratory tract infection (n=12, 7.0%). No specific trigger 
was identified in 10 patients (5.8%). These admissions were considered to be related to 
anxiety or for symptomatic control, with unchanged CT appearances and normal blood tests. 
Twenty-seven admissions (15.7%) were due to an acute exacerbation of IPF (AE-IPF), of which 
26 were considered to be triggered events. Extra-parenchymal pathology was the cause of 
the ARD-IPF in 9 (5.2%) cases.  
In approximately one third of patients (n=56, 32.6%), a CT scan was not performed as part of 
the admission and therefore it was felt that the cause for the ARD could not be fully 
characterised. All patients in this group had no new features reported on their CXR (by 
consultant radiologist). Of these, 55% (n=31) had a CRP ≥ 50mg/L and thus infection may have 
been a trigger. 
Clinical characteristics of ARD-IPF
The characteristics of patients admitted with an AE-IPF, as their first ARD-IPF, were compared 
to those presenting with other parenchymal causes and those with an uncharacterised ARD-
IPF. Patients admitted with an AE-IPF were significantly younger than those admitted with 
other parenchymal causes for their respiratory deterioration (AE-IPF 75 years (IQR 66-80) vs 
parenchymal cause 81 years (IQR 71-86), but had comparable baseline CURB-65 and NEWS-2 
scores, GAP stage, lung physiology and 6MWT parameters. 
Investigation of ARD-IPF  
A potentially pathogenic organism was detected in 12.2% (n=21) of first ARD-IPF admissions 
(Table 2). Culture of sputum was the most common technique to detect a pathogen; 
accounting for 76.2% of all positive microbiological samples. Bronchoalveolar lavage (BAL) 
was rarely performed (n=6). The most commonly identified pathogen was Pseudomonas 
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Of those patients with a triggered AE-IPF, 4 patients had positive microbiological test results 
for Pseudomonas aeruginosa, Haemophilus influenzae, alpha haemolytic Streptococcus 
species and Cytomegalovirus (Supplementary Table 2). 
Management of ARD-IPF 
Three patients within the AE-IPF group, received invasive mechanical ventilation during their 
admission. All survived to hospital discharge; with a median length of stay of 20 days (IQR 14-
42) and remained alive at 30 days post discharge (Table 3). No other patients presenting with 
ARD-IPF received IMV.
Antibiotics were used almost ubiquitously for patients admitted with a first episode of ARD-
IPF (94.7%, n=163 of 172 first admissions), with a median duration of 10 days (IQR 7-14). There 
was no significant difference in the use of antibiotics for management of AE-IPF compared to 
with those with a parenchymal cause for ARD-IPF other than an AE.  
Corticosteroids formed part of the treatment of 43% (n=74) of first admissions with ARD-IPF. 
Approximately one third of AE-IPF (n=9, 33.3%) and parenchymal ARD-IPF (n=25, 31.3%) 
received oral corticosteroids, whilst a minority (n=4 AE-IPF, n=11  other parenchymal causes) 
received methylprednisolone (standard regime 500-750mg methylprednisolone IV daily over 
3 consecutive days).  
Primary Outcome  
Short term mortality associated with first admissions with ARD-IPF was high; 17% of ARD-IPF 
admissions died as an inpatient, 22% within 30 days and 36% within 90 days of presentation 
(Table 3). There was no significant difference in the in-hospital, 30 day or 90 day mortality 
between uncharacterised, AE-IPF and parenchymal ARD-IPF.
Logistic regression analysis (Table 4a and Table 4b) was performed to assess risk factors 
associated with an independent increased risk of in-hospital and 90-day mortality of patients 
admitted with their first ARD-IPF and for all ARD-IPF patients. Baseline NEWS-2 and CURB-65 
scores were predictive of in-hospital mortality for all ARD-IPF admissions (Odd’s ratios: OR 
4.06, P=<0.001; OR 4.08, P=0.007, respectively). Similarly, baseline NEWS-2, CURB-65 and 
GAP score were predictive of 90 day mortality in all ARD-IPF admissions (OR 1.74, P<0.001; 
OR 2.32, P=0.003; OR 1.58, P=0.023, respectively). 
ROC curve analysis suggested that baseline CURB-65 and NEWS-2 gave the highest area under 
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Figure 1). Using the maximum Youden’s index for each variable, baseline CURB-65 >3.5 and 
NEWS-2 score >6.5 were identified as the optimum cut-offs for predicting in-hospital 
mortality (Table 5).
Secondary Outcomes 
The median length of stay (LOS) for all patients admitted with their first ARD-IPF was 7 days 
(IQR 3-14). There was no significant difference in the LOS when comparing first admission 
with all admissions of ARD-IPF. In contrast, patients with an uncharacterised ARD-IPF had a 
significantly shorter LOS compared to those with a parenchymal cause of deterioration other 
than AE (median LOS uncharacterised 4 days (IQR 2-10) vs parenchymal 8 days (IQR 4-17) 
p=0.008), with no significant difference between AE-IPF and parenchymal ARD-IPF subgroups.  
Discussion
In this single centre retrospective observational study, we examined the clinical 
characteristics of patients admitted with an ARD-IPF, at a UK hospital providing specialist ILD 
facilities. Our findings suggest there is significant mortality related to hospitalisations with 
ARD-IPF of any underlying cause. NEWS-2 and CURB-65 illness severity scores were 
independent predictors of mortality and may provide a simple tool to help future 
prognostication.  
AE-IPF are known to be associated with high mortality and poor prognosis (18). Our data show 
that all ARD-IPF, not just AE-IPF, are associated with significant mortality. This finding is in 
concordance with Moua and colleagues (19), who demonstrated significant mortality 
associated with acute respiratory worsening (almost 80% at one year), irrespective of the 
underlying fibrotic lung disease or cause of respiratory decline. Our overall 90-day mortality 
rate for first ARD-IPF was comparable to that reported by other groups (5). In our cohort, 
there was no significant difference in mortality between AE-IPF and other parenchymal 
causes of ARD-IPF. This is in contrast to the findings of Teramachi et al. (5) who showed the 
90-day mortality of AE-IPF patients was significantly higher compared to ARD of other 
parenchymal causes (46% (16/35) vs 17% (12/71) respectively; P = 0.002). These apparently 
conflicting findings may in part be explained by differences in study populations; an older 
population in our study and parenchymal causes of ARD-IPF included those with cardiac 
failure/fluid overload. Our findings also suggest that whilst clinicians should endeavour to 
make practical attempts at defining the cause for deterioration, clinicians/patients/families 
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those such as, pulmonary embolism or pneumonia/infection that may be considered as a 
potentially ‘reversible cause’ of breathlessness in an isolated context.  
The identification of patients with poor prognosis from ARD-IPF remains a significant 
challenge for clinicians. Baseline FVC, TLCO, 6MWT parameters and even GAP-stage were not 
consistently independent predictors of outcome in this cohort, whilst increasing NEWS-2 and 
CURB-65 scores were independent predictors of both in-hospital and 90-day mortality for all 
ARD-IPF. Previous studies have reported several prognostic factors in patients with AE-IPF, 
including age, sex, symptom duration, smoking history, FVC and TLCO (20-22), but have not 
to our knowledge, investigated the role of these illness severity or early warning scores. We 
propose potential cut-offs for baseline CURB-65 and NEWS-2 scores through ROC curve and 
sensitivity analysis, although acknowledge that independent validation is required. If these 
finding are confirmed, then NEWS-2 and CURB-65 may prove simple and helpful tools in 
guiding prognostication of patients with ARD-IPF. 
Post mortem samples (23, 24) and epidemiological data (25) both suggest that infection may 
be a triggering insult in some AE-IPF, although it remains unclear if a small number of specific 
pathogens are responsible for the majority of these cases and if there is a relationship 
between an identified pathogen and patient outcome. Our data shows that an infectious 
pathogen was identified in only a minority of patients admitted with ARD-IPF (12%) and as 
such, comparative analysis based on outcome could not be undertaken. The organisms 
isolated were predominantly gram-negative bacteria or ‘cold-associated’ viruses and in 
keeping with the findings of previous studies (26). One patient demonstrated CMV on BAL, 
associated with a positive viral PCR throat swab, but absence of peripheral blood 
antigenaemia, suggesting CMV colonisation rather than infection and supporting the 
assertion of latent infection and/or abnormal colonisation in the lungs of many IPF patients 
(26). 
Antibiotics were used almost ubiquitously in cases of hospitalised ARD-IPF (94.7%), perhaps 
indicating that for clinicians, it is often impossible to exclude underlying infection as a 
potential contributor in these episodes. Almost half of all patients with AE-IPF, and 43% of 
ARD-IPF, received corticosteroids during their admission, although there is no clear evidence 
to support this approach. Current ATS/ERS IPF guidance makes a ‘weak recommendation’ for 
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high mortality associated with these episodes (1). Thus, there remains a clear need for high-
quality controlled studies to support the evidence-based management of ARD-IPF.  
Accurate definition of an AE-IPF was a significant challenge to this study, contributing to the 
small numbers reported and in part was related to missing data; CT Chest imaging was only 
performed in approximately 40% of first admissions with ARD-IPF, despite being 
recommended as part of the initial investigation to diagnose AE-IPF (4).  Whilst this is in 
keeping with some of the available published studies (19, 27), it is considerably lower than 
that reported by Teramachi et al. in Japan (5). We suggest that combination of factors may 
explain these differences which may reflect the practice of initial treating non-ILD-specialists, 
patient preference and/or not practically possible or reasonable given the illness severity of 
the patient. That said, accurate definition of an AE-IPF is not unique challenge to our cohort; 
data from three IPFnet trials showed that 35% (31 of 88) of investigator-reported AE-IPF were 
subsequently categorised as unclassifiable because of missing data (28). 
Other potential limitations of this relatively small observational study are acknowledged and 
include those intrinsic to retrospective studies, such as missing data and lack of appropriate 
controls. The identification of patients relied on a search of clinical coding databases and as 
such, the true incidence of ARD-IPF may not have been fully captured. This is a single centre 
experience and as such the findings might not be generalisable to other populations, 
particularly since this was an entirely Caucasian cohort. Whilst the study was a single centre 
study, the population described in this manuscript was heterogeneous in terms of aetiology 
of respiratory deterioration and a multicentre study may provide comparable data. 
Nonetheless, we are planning future multicentre validation and this initial single centre pilot 
work will provide valuable feasibility data to influence the scope and size of such work. 
In conclusion, our findings suggest there is significant morbidity related to hospitalisation with 
ARD-IPF of any underlying cause, with both NEWS-2 and CURB-65 providing independent 
prediction of in-hospital and 90 day mortality. Further prospective work should be 
undertaken to verify these findings and refine the management of these episodes, particularly 
given the widespread use of antibiotics in this cohort. Given the significant 90-day post-
hospitalisation mortality, if survival to discharge from ARD is achieved, early consideration for 
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Table 1. Characteristics of patients admitted with their first and all acute respiratory 
deterioration of idiopathic pulmonary fibrosis (ARD-IPF). Comparison of AE-IPF with those 
presenting with other parenchymal causes or an uncharacterised episode of ARD-IPF. There 
were no statistically significant differences between baseline characteristics of first and all 
admissions for ARD-IPF. Patients admitted with an AE-IPF were significantly younger than 
those admitted with other parenchymal causes for their respiratory deterioration (AE-IPF 75 
years (IQR 66-80) vs parenchymal cause 81 years (IQR 71-86), but had comparable baseline 
NEWS-2 scores, GAP stage, lung physiology and 6MWT parameters. C-reactive protein was 
statistically higher in patients with AE-IPF than in patients with other parenchymal causes of 
ARD: 75mg/L (IQR 26-126) versus 34mg/L (IQR 12-73), respectively. Data presented as median 
and interquartile ranges (continuous data) or numbers and percentages (categorical). 
Continuous data analysed using Kruskal Wallis testing. Categorical data analysed using Chi-
squared testing. *P<0.05 was considered statistically significant.
Abbreviations: NEWS-2, National Early Warning Score 2; WBC, White blood count; NLR, 
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exacerbation; P, parenchymal; GAP, gender, age, physiology; n, number; %, percentage; FVC, 
Forced vital capacity; TLCO, transfer factor for carbon monoxide; UIP, usual interstitial 
pneumonia. 
Table 2: Microbiological investigations undertaken for first admissions with acute 
respiratory deteriorations of idiopathic pulmonary fibrosis (ARD-IPF). Abbreviations: n, 
number; %, percentage; MC&S, microscopy, culture and sensitvity; UAT, urinary antigen 
testing; PCR, polymerase chain reaction. * Sputum culture identified Coliforms (2), 
Haemophillus influenzae (1), Moraxella catarrhalis (3), Pseudomonas aeruginosa (7), 
Raoutella plantiola (1), Serratia marcescans (1) and Streptococcus pneumoniae (1). ** Blood 
culture revealed Pseudomonas aeruginosa infection. # Oropharyngeal viral PCR revealed 
Cytomegalovirus (CMV) (1), Influenza A (1), Rhinovirus (2) and Respiratory Syncytial Virus (1). 
† Bronchoalveolar lavage identified CMV (1), alpha haemolytic streptococcus (1) and 
Pseudomonas aeruginosa (1). One patient was identified with pseudomonas both in sputum 
and blood cultures. One patient had both rhinovirus positivity on viral PCR and streptococcus 
pneumoniae in sputum culture. 
Table 3. Outcomes of patients admitted with their first and all acute respiratory 
deterioration of idiopathic pulmonary fibrosis (ARD-IPF). Comparison of AE-IPF with those 
presenting with other parenchymal causes or an uncharacterised episode of ARD-IPF. There 
was no statistical difference in the length of antibiotics, use of corticosteroids, level of 
respiratory support or mortality between groups. Patients with an uncharacterised ARD-IPF 
had a significantly shorter LOS compared to those with a parenchymal cause of deterioration 
other than AE (median LOS uncharacterised 4 days (IQR 2-10) vs parenchymal 8 days (IQR 4-
17) p=0.008. Data presented as median and interquartile ranges (continuous data) or 
numbers and percentages (categorical). Continuous data analysed using Kruskal Wallis 
testing. Categorical data analysed using Chi-squared testing. *P<0.05 was considered 
statistically significant. Abbreviations: n, number; IV, intravenous; IQR, interquartile range. 
LOS, length of stay; AE, acute exacerbation; U, uncharacterised; P, parenchymal; HFNO, high 
flow nasal oxygen, NIV, non-invasive ventilation, IMV, invasive mechanical ventilation, %, 
percentage.
Table 4: Association of baseline patient factors with a) in-hospital mortality (top) b) 90-day 
mortality (below) following first admission and all admissions with ARD-IPF. Odds ratios 
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independently predicting mortality. Baseline NEWS-2 and CURB-65 scores were predictive of 
in-hospital mortality for all ARD-IPF admissions (OR 4.06, p=<0.001; OR 4.08, p=0.007, 
respectively). Similarly, baseline NEWS-2, CURB-65 and GAP score were predictive of 90 day 
mortality in all ARD-IPF admissions (OR 1.74, <0.001; 2.32, 0.003; 1.58, 0.023, respectively). 
In this cohort, male gender was associated with increased survival of all ARD-IPF patients as 
in-patients and also at 90-days for those with a first admission of ARD-IPF  (- OR 0.07; p= 0.019 
and OR 0.1; p=0.031, respectively).
Table 5: Outcomes of receiver operating characteristic (ROC) curve analysis for determining 
the optimal cut-off values for CURB-65 and NEWS-2 scores, correlating with in-hospital or 
90-day mortality in all acute respiratory deteriorations of Idiopathic Pulmonary fibrosis 
(ARD-IPF). ROC curve analysis suggested that baseline CURB-65 and NEWS-2 gave the highest 
area under the curve (AUC) values for in-hospital mortality, 0.847 and 0.889 respectively 
Abbreviations : AUC, Area under the curve; CI, confidence interval; P, significance value; % 
percentage.
Supplementary Table 1: Additional baseline demographics of patients admitted with their 
first acute respiratory deterioration of idiopathic pulmonary fibrosis (ARD-IPF). 
Abbreviations: IQR, interquartile range; n, number; FVC, Forced vital capacity; TLCO, transfer 
factor for carbon monoxide; GAP, gender-age-physiology; MDT, multidisciplinary team; UIP, 
usual interstitial pneumonia; %, percentage.
Supplementary Table 2: Microbiological test results in patients presenting with AE-IPF, 
parenchymal or un-characterised ARD. ^^  Pseudomonas aeruginosa (1), Haemophilus 
influenzae (1). * Both sputum and blood cultures grew the same organism, Pseudomonas 
aeruginosa. + One patient had co-infection with rhinovirus and Streptococcus pneumoniae. ^ 
Alpha haemolytic Streptococcus species and Cytomegalovirus infection. ++ same organism 
identified in sputum and on BAL, Pseudomonas aeruginosa. Abbreviations: n, number; CRP, 
C-reactive protein; PCR, Polymerase chain reaction; BAL, bronchoalveolar lavage. 
Supplementary Figure 1: Receiver operating characteristics (ROC) curve analysis of baseline 
CURB-65 and NEWS-2 scores for in-hospital and 90-day mortality following admission for an 
acute respiratory deterioration of Idiopathic Pulmonary Fibrosis. CURB-65 and NEWS-2 for in-
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Figure 1: Aetiology of first admissions with acute respiratory deteriorations of Idiopathic Pulmonary Fibrosis 
(ARD-IPF).  ARD-IPF were subdivided according to the conceptual framework as published by Collard et al. 
(4).  Abbreviations: AE-IPF, acute exacerbation of IPF; n, number; LRTI, Lower respiratory tract infection; 
CRP, C-reactive protein; CT, Computed Tomography of Chest. 
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Table 1. Characteristics of patients admitted with their first and all acute respiratory deterioration of idiopathic pulmonary fibrosis (ARD-IPF). Comparison 
of AE-IPF with those presenting with other parenchymal causes or an uncharacterised episode of ARD-IPF. There were no statistically significant differences 












Age (median, IQR) 77 (70-85) - - 77 (71-85) 75 (66-80) 81 (71-86) 0.035*
AE vs P
Gender, males, n (%) 108 (62.8) - - 31 (55.4) 21 (77.8) 51 (63.8) 0.208
Total GAP score (median, IQR) 5 (4-6), n=116 - - 5 (3-6), n=39 5 (4-6), n=19 4.5 (4-5), n=52 0.810

















6-minute walk test (6MWT) 
(median, IQR)
6MWT distance (m)















CURB-65 Score, n (%)       
0-1 32 (18.6) 40 (17.2) 0.923 13 (23.2) 7 (25.9) 11 (13.8) 0.550
2 70 (40.7) 94 (40.5) 23 (41.1) 10 (37.0) 35 (43.8)
≥ 3 70 (40.7) 98 (42.2) 20 (35.7) 10 (37.0) 34 42.5)
NEWS-2 Score, n (%)       
 0 0 (0) 0 (0) 0.991 0 (0) 0 (0) 0 (0) >0.999
 1-4 93 (54.1) 125 (53.9) 31 (55.4) 15 (55.6) 31 (38.8)
 5-6 48 (27.9) 66 (28.4) 17 (30.4) 8 (29.6) 17 (21.3)
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other parenchymal causes for their respiratory deterioration (AE-IPF 75 years (IQR 66-80) vs parenchymal cause 81 years (IQR 71-86), but had comparable 
baseline NEWS-2 scores, GAP stage, lung physiology and 6MWT parameters. C-reactive protein was statistically higher in patients with AE-IPF than in patients 
with other parenchymal causes of ARD: 75mg/L (IQR 26-126) versus 34mg/L (IQR 12-73), respectively. Data presented as median and interquartile ranges 
(continuous data) or numbers and percentages (categorical). Continuous data analysed using Kruskal Wallis testing. Categorical data analysed using Chi-squared 
testing. *P<0.05 was considered statistically significant.
Abbreviations: NEWS-2, National Early Warning Score 2; WBC, White blood count; NLR, neutrophil: lymphocyte ratio; CRP, C-reactive protein; IQR, interquartile 
range; AE, acute exacerbation; P, parenchymal; GAP, gender, age, physiology; n, number; %, percentage; FVC, Forced vital capacity; TLCO, transfer factor for 
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Microbiological Test, n (%) First Admission
(Total n=172)
Data presented as n, (%)
No pathogen identified 151 (87.8)
Pathogen identified 21 (12.2)
Sputum MC&S
     Not performed/rejected 95 (55.2)
     Negative culture 52 (30.2)
     Non-specific culture 9 (5.2)
     Positive culture * 16 (9.3)
Blood Culture 
     Not performed 80 (46.5)
     Negative culture 91 (52.9)
     Positive culture ** 1 (0.6)
Pneumococcal UAT
     Not performed 128 (74.4)
     Negative result 44 (25.6)
Oropharyngeal viral PCR
     Not performed 144 (83.7)
     Negative result 23 (13.4)
     Positive result # 5 (2.9)
Other positive microbiological tests
   Atypical pneumonia serology 
   Bronchoalveolar lavage †
1
3 
Table 2: Microbiological investigations undertaken for first admissions with acute 
respiratory deteriorations of idiopathic pulmonary fibrosis (ARD-IPF). Abbreviations: n, 
number; %, percentage; MC&S, microscopy, culture and sensitvity; UAT, urinary antigen 
testing; PCR, polymerase chain reaction. * Sputum culture identified Coliforms (2), 
Haemophillus influenzae (1), Moraxella catarrhalis (3), Pseudomonas aeruginosa (7), 
Raoutella plantiola (1), Serratia marcescans (1) and Streptococcus pneumoniae (1). ** Blood 
culture revealed Pseudomonas aeruginosa infection. # Oropharyngeal viral PCR revealed 
Cytomegalovirus (CMV) (1), Influenza A (1), Rhinovirus (2) and Respiratory Syncytial Virus (1). 
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Pseudomonas aeruginosa (1). One patient was identified with pseudomonas both in sputum 
and blood cultures. One patient had both rhinovirus positivity on viral PCR and streptococcus 
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Table 3. Outcomes of patients admitted with their first and all acute respiratory deterioration of idiopathic pulmonary fibrosis (ARD-IPF). Comparison of AE-
IPF with those presenting with other parenchymal causes or an uncharacterised episode of ARD-IPF. There was no statistical difference in the length of 
antibiotics, use of corticosteroids, level of respiratory support or mortality between groups. Patients with an uncharacterised ARD-IPF had a significantly shorter 














































Received antibiotics (> 2 days), n (%) 163 (94.7) 217 (93.7) 0.674 54 (96.4) 20 (100.0) 75 (93.8) n/s
Duration antibiotic course, days, 
(median, IQR)
    















Oral corticosteroids, n (%) 51 (29.7) 68 (29.3) >0.99 16 (28.6) 9 (33.3) 25 (31.3)
IV corticosteroids, n (%) 23 (13.4) 30 (12.9) >0.99 6 (10.7) 4 (14.8) 11 (13.8)
Hospital length of stay, days,  
(median, IQR) 7 (3-14) 7 (3-14) 0.901 4 (2-10) 9 (4-17) 8 (4-17) 0.008* 
U vs P
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Data presented as median and interquartile ranges (continuous data) or numbers and percentages (categorical). Continuous data analysed using Kruskal Wallis 
testing. Categorical data analysed using Chi-squared testing. *P<0.05 was considered statistically significant.
Abbreviations: n, number; IV, intravenous; IQR, interquartile range. LOS, length of stay; AE, acute exacerbation; U, uncharacterised; P, parenchymal; HFNO, 
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a)
b)
Table 4: Association of baseline patient factors with a) in-hospital mortality (top) b) 90-day 
mortality (below) following first admission and all admissions with ARD-IPF. Odds ratios (OR) were 
calculated and logistic regression analyses performed to identify factors independently predicting 
mortality. Baseline NEWS-2 and CURB-65 scores were predictive of in-hospital mortality for all ARD-
IPF admissions (OR 4.06, p=<0.001; OR 4.08, p=0.007, respectively). Similarly, baseline NEWS-2, 
CURB-65 and GAP score were predictive of 90 day mortality in all ARD-IPF admissions (OR 1.74, 
<0.001; 2.32, 0.003; 1.58, 0.023, respectively). In this cohort, male gender was associated with 
First admission with ARD-IPF All ARD-IPF
Variable Odds Ratio (C.I.) P value Odds Ratio (C.I.) P value
Male 0.03 (0.00-9.18) 0.227 0.07 (0.01-0.65) 0.019
Age 1.15 (0.94-1.41) 0.175 1.02 (0.94-1.11) 0.564
Smoking status 0.40 (0.01-24.7) 0.665 1.65 (0.38-7.15) 0.501
GAP 0.45 (0.69-2.98) 0.409 1.04 (0.56-1.91) 0.912
WCC 0.79 (0.48-1.31) 0.363 0.90 (0.75-1.08) 0.260
NLR 0.95 (0.80-1.13) 0.559 1.04 (0.92-1.18) 0.528
CRP 1.02 (0.98-1.05) 0.376 1.01 (1.00-1.01) 0.171
NEWS-2 6.68 (1.42-31.3) 0.016 4.06 (2.23-7.41) <0.001
CURB-65 10.03 (0.24-420.8) 0.227 4.08 (1.47-11.31) 0.007
First admission with ARD-IPF All ARD-IPF
Variable Odds Ratio (C.I.) P value Odds Ratio (C.I.) P value
Male 0.10 (0.01-0.82) 0.031 0.36 (0.11-1.15) 0.084
Age 1.02 (0.95-1.10) 0.506 1.01 (0.96-1.05) 0.770
Smoking status 1.16 (0.23-5.81) 0.854 1.34 (0.58-3.08) 0.494
GAP 2.51 (1.16-5.41) 0.019 1.58 (1.06-2.34) 0.023
WCC 1.12 (0.92-1.37) 0.267 1.02 (0.92-1.12) 0.735
NLR 1.00 (0.94-1.06) 0.931 0.98 (0.94-1.03) 0.498
CRP 1.00 (1.00-1.01) 0.518 1.00 (1.00-1.01) 0.074
NEWS-2 1.40 (0.99-2.03) 0.074 1.74 (1.37-2.21) <0.001
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increased survival of all ARD-IPF patients as in-patients and also at 90-days for those with a first 
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0.847 0.774 to 0.920 <0.0001 >3.5 94.8 67.5 0.62
CURB-65 
90 day mortality
0.763 0.696 to 0.830 <0.0001 >3.5 98.6 41.2 0.40
NEWS-2 in-hospital 
mortality
0.889 0.820 to 0.958 <0.0001 >6.5 94.3 75.0 0.69
NEWS-2 
90 day mortality
0.744 0.674 to 0.815 <0.0001 >5.5 86.4 55.3 0.42
Table 5: Outcomes of receiver operating characteristic (ROC) curve analysis for determining 
the optimal cut-off values for CURB-65 and NEWS-2 scores, correlating with in-hospital or 
90-day mortality in all acute respiratory deteriorations of Idiopathic Pulmonary fibrosis 
(ARD-IPF). ROC curve analysis suggested that baseline CURB-65 and NEWS-2 gave the highest 
area under the curve (AUC) values for in-hospital mortality, 0.847 and 0.889 respectively. 
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